Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity results from UNCOVER-2 and UNCOVER-3 /
PURPOSE: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity. MATERIALS AND METHODS: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W)...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | JOURNAL OF DERMATOLOGICAL TREATMENT
30 No. 1 |
| doi: | 10.1080/09546634.2018.1473551 |
| mtmt: | 3370300 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/20075 |
| Tartalmi kivonat: | PURPOSE: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity. MATERIALS AND METHODS: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W), or 50-mg etanercept (ETN) biweekly for 12 weeks, then open-label IXEQ4W (UNCOVER-3). Psoriasis severity was categorized by baseline Psoriasis Area and Severity Index (PASI <20 and >/=20). Efficacy was evaluated by percentage reaching PASI 75, 90, 100, and absolute PASI </=5, </=2, and </=1. RESULTS: Significantly more patients with PASI >/=20 (vs. PASI <20) were male and had higher body weight. After 12 weeks, both severity groups had significantly more IXEQ2W- than ETN-treated patients reach PASI 75, 90, 100, and absolute PASI </=5, </=2, </=1. Fewer PASI >/=20 vs. PASI <20 patients across treatments reached PASI </=5, </=2, and </=1 at Week 12. Efficacy was maintained during 156 weeks of ixekizumab treatment with no differences between groups. The IXEQ2W safety profile was similar between groups except for injection-site reactions (significantly higher in PASI <20). CONCLUSIONS: Ixekizumab demonstrated a high level of efficacy and had a consistent safety profile in patients with different baseline psoriasis severity levels. |
|---|---|
| Terjedelem/Fizikai jellemzők: | 19-26 |
| ISSN: | 0954-6634 |